Paper31300331
Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial.
Tinto H and 17 others. Lancet Infect Dis, 2019. Cited by 54 papers, by iCite.
Cite this record
ConductScience Library. Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial. Papers, record 31300331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31300331
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial.
- PubMed
- Publication types
- Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Malaria | Major topic |
| Malaria Vaccines | Major topic |
| Severity of Illness Index | Major topic |
| Vaccination | Major topic |
| Africa | |
| Child | |
| Child, Preschool | |
| Female | |
| Humans | |
| Incidence | |
| Infant | |
| Male |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT02207816 | An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa | Background | Yes |
Source ClinicalTrials.gov
Cited by41
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 54 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41882671 | Public health impact of catch-up vaccination or additional booster doses with pre-erythrocytic malaria vaccine R21/Matrix-M: a modelling study. | BMC Med | 2026 | https://conductscience.org/library/papers/41882671 | PubMed |
| 41873526 | Robust Bioconjugated Antigens Induce Immune Responses Preventing Malaria Infection and its Transmission. | Small | 2026 | https://conductscience.org/library/papers/41873526 | PubMed |
| 41629565 | mRNA vaccination overcomes haemozoin-mediated impairment of whole-parasite malaria vaccines in mice. | Nat Microbiol | 2026 | https://conductscience.org/library/papers/41629565 | PubMed |
| 41279441 | mRNA vaccination overcomes hemozoin-mediated impairment of whole parasite vaccine efficacy for malaria. | bioRxiv | 2025 | https://conductscience.org/library/papers/41279441 | PubMed |
| 40975080 | Sustained efficacy of the RTS,S/AS01E malaria vaccine over 50 months of follow-up when used in full-dose or fractional-dose regimens in young children in Ghana and Kenya: final results from an open-label, phase 2b, randomised controlled trial. | Lancet Glob Health | 2025 | https://conductscience.org/library/papers/40975080 | PubMed |
| 40799456 | Mapping climate change-driven epidemics. | Front Epidemiol | 2025 | https://conductscience.org/library/papers/40799456 | PubMed |
| 39854359 | A systematic review on malaria and Tuberculosis (TB) vaccine challenges in sub-Saharan African clinical trials. | PLoS One | 2025 | https://conductscience.org/library/papers/39854359 | PubMed |
| 38764069 | IgG and IgM responses to the Plasmodium falciparum asexual stage antigens reflect respectively protection against malaria during pregnancy and infanthood. | Malar J | 2024 | https://conductscience.org/library/papers/38764069 | PubMed |
| 38441731 | Malaria vaccine efficacy, safety, and community perception in Africa: a scoping review of recent empirical studies. | Infection | 2024 | https://conductscience.org/library/papers/38441731 | PubMed |
| 38438123 | Could Less Be More? Accounting for Fractional-Dose Regimens and Different Number of Vaccine Doses When Measuring the Impact of the RTS,S/AS01E Malaria Vaccine. | J Infect Dis | 2024 | https://conductscience.org/library/papers/38438123 | PubMed |
| 38430916 | Integration of the RTS,S/AS01 malaria vaccine into the Essential Programme on Immunisation in western Kenya: a qualitative longitudinal study from the health system perspective. | Lancet Glob Health | 2024 | https://conductscience.org/library/papers/38430916 | PubMed |
| 37872492 | Background malaria incidence and parasitemia during the three-dose RTS,S/AS01 vaccination series do not reduce magnitude of antibody response nor efficacy against the first case of malaria. | BMC Infect Dis | 2023 | https://conductscience.org/library/papers/37872492 | PubMed |
| 37793915 | Malaria vaccine-related adverse events among children under 5 in sub-Saharan Africa: systematic review and meta-analysis protocol. | BMJ Open | 2023 | https://conductscience.org/library/papers/37793915 | PubMed |
| 36547910 | Polypharmacological Cell-Penetrating Peptides from Venomous Marine Animals Based on Immunomodulating, Antimicrobial, and Anticancer Properties. | Mar Drugs | 2022 | https://conductscience.org/library/papers/36547910 | PubMed |
| 36504817 | Vesicular stomatitis virus-based vaccine targeting plasmodium blood-stage antigens elicits immune response and protects against malaria with protein booster strategy. | Front Microbiol | 2022 | https://conductscience.org/library/papers/36504817 | PubMed |
| 36146602 | Mouse Models for Unravelling Immunology of Blood Stage Malaria. | Vaccines (Basel) | 2022 | https://conductscience.org/library/papers/36146602 | PubMed |
| 36119062 | Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children. | Front Immunol | 2022 | https://conductscience.org/library/papers/36119062 | PubMed |
| 36093265 | RTS,S/AS01 malaria vaccine (Mosquirix®): a profile of its use. | Drugs Ther Perspect | 2022 | https://conductscience.org/library/papers/36093265 | PubMed |
| 35915227 | Vaccine co-display of CSP and Pfs230 on liposomes targeting two Plasmodium falciparum differentiation stages. | Commun Biol | 2022 | https://conductscience.org/library/papers/35915227 | PubMed |
| 35899811 | Malaria Transmission Intensity Likely Modifies RTS, S/AS01 Efficacy Due to a Rebound Effect in Ghana, Malawi, and Gabon. | J Infect Dis | 2022 | https://conductscience.org/library/papers/35899811 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31300331
GET https://conductscience.org/api/papers/v1/31300331/cited_by?page=2